Europe

Almirall, Quintiles sign long-term commercial U.K. partnership

Monday, July 30, 2012 10:52 AM

Global pharmaceutical company Almirall and Quintiles, a fully integrated biopharmaceutical services company, have reached a long-term strategic partnership agreement to promote Almirall’s respiratory portfolio in the U.K. commencing with a new, long-acting antimuscarinic (LAMA) delivered via an innovative, multi-dose inhaler for the treatment of chronic obstructive pulmonary disease (COPD).

More... »

EFPIA supports E.C. adoption of clinical trials regulation

Monday, July 23, 2012 01:01 PM

The European Federation of Pharmaceutical Industries and Associations (EFPIA), a group of 33 European national pharmaceutical industry associations and 35 companies, welcomes the proposal for a new regulation on clinical trials on medicinal products for human use adopted July 23 by the European Commission as a first step towards further cooperation in the clinical trials assessment process across the E.U.

More... »

Novasep invests $3.6M to boost HPAPI manufacturing capabilities

Monday, July 23, 2012 12:27 PM

Novasep, a global supplier of manufacturing solutions to the life sciences industries, has invested $3.6 million to expand its Highly Potent API (HPAPI) manufacturing capabilities at its facility in Le Mans, France. The expansion has been designed to allow Novasep to serve the increased demand for manufacturing of novel anti-cancer therapies.

More... »

Oracle to support Cancer Research U.K.’s development of targeted cancer therapies

Tuesday, July 17, 2012 12:05 PM

To support its vision of beating cancer in the United Kingdom, Cancer Research U.K., , a not-for-profit cancer research organization, will work with Oracle Health Sciences Translational Research Center as the foundation for a new analytical environment to help the charity combine the genetic and clinical data from its Stratified Medicine Program.

More... »

Actelion to cut jobs, refocus R&D

Friday, July 13, 2012 03:17 PM

Switzerland-based Actelion has launched a cost saving initiative as an integral part of its strategy for value creation outlined in early May. The initiative will cut up to 135 positions and refocusing the company’s R&D activities toward orphan and specialty indications to generate additional specialty franchises, enabling it to fully capitalize on the significant growth opportunities in its core area of expertise of pulmonary arterial hypertension (PAH).

More... »

Calixar, Synthelis to provide unique membrane protein services

Friday, July 6, 2012 01:51 PM

Calixar, a French company that isolates and crystallizes native and functional membrane proteins, and Synthelis, a French company specializing in the production and vectorization of these same molecules, have entered into an alliance for the production and isolation of all types of target membrane proteins.

More... »

Prosonix, Imperial College London collaborate on engineered combo respiratory meds

Thursday, July 5, 2012 02:43 PM

Prosonix, a speciality pharmaceutical company of Oxford, U.K., has signed a collaborative research agreement with Imperial College London to accelerate the development of engineered multi-component particles (MCPs) as respiratory medicines.

More... »

Concern as NHS spending on advanced medicines to decline

Tuesday, July 3, 2012 02:29 PM

A new forecast by the Office of Health Economics, for the ABPI, has shown that total National Health Service (NHS) spending on medicines is well under control, while expenditure on innovative branded medicines is actually set to shrink in real terms and as a proportion of the healthcare budget over the next three years.

More... »

Medicyte coordinates E.U.-funded collaboration on biomimetic bioartificial liver

Tuesday, July 3, 2012 01:57 PM

Medicyte, The Electrospinning Company and the Universities of Manchester and Pisa have launched a European-wide project, the Re-liver Consortium, aimed to design a biomimetic bioartificial liver.

More... »

Ferring acquires licensing rights for Albireo’s elobixibat for irritable bowel

Tuesday, July 3, 2012 11:06 AM

Swiss research-driven specialty biopharmaceutical group Ferring Pharmaceuticals and Swedish biotech Albireo have signed a license agreement under which Ferring has rights to develop and commercialize elobixibat, a first-in-class compound for chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C).

More... »